Carpenter D, Sin G. “Policy Tragedy and the Emergence of Regulation: The Food Drug and Cosmetic Act of 1938”. Studies in American Political Development . 2007;21 (2) :149-180.

Carpenter D, Ting M. “Regulatory Errors with Endogenous Agendas”. American Journal of Political Science . 2007;51 (4) :835-853. regulatory_error_with_endogenous_agendas_-_ajpspublished.pdf

Carpenter D, Moore CD, Glassman M, Skowronek S. “Robust Action and the Strategic Use of Ambiguity in a Bureaucratic Cohort: FDA Scientists and the Investigational New Drug Regulations of 1963”. Formative Acts: American Politics in the Making . 2007.

Carpenter D. “Reputation Gatekeeping and the Politics of Post-marketing Drug Regulation”. Virtual Mentor [American Medical Association] . 2006;8 :403-406. Publisher's Version

Carpenter D, Armstrong E, Hojnacki M. “Whose Deaths Matter? Mortality Identity and Attention to Disease in the Mass Media”. Journal of Health Politics Policy and Law . 2006;31 (4) :729-772.

Carpenter D. A Simple Theory of Placebo Learning with Self-Remitting Conditions. 2005. placeboremit.pdf

Carpenter D, Ting M. “The Political Logic of Regulatory Error” . Nature Reviews – Drug Discovery . 2005;4 (10) :819-823.

Carpenter D. “A Modest Proposal for Financing Postmarketing Drug Safety Studies by Augmenting FDA User Fees” . Health Affairs – Web Exclusive . 2005;W5 (469).

Carpenter D, Aberbach JD, Peterson M, of Branch TIAD: TE. “The Evolution of National Bureaucracy in the United States”. 2005 :41-71.

Carpenter D, Feinstein B, Moore C, Turenne M, Yohai I, Zucker EJ. Why Do Bigger Firms Receive Faster Drug Approvals?. 2004. whybigfast1.pdf

Carpenter D, Esterling K, Lazer D. “Friends Brokers and Transitivity: Who Talks with Whom in Washington Lobbying?” . Journal of Politics . 2004;66 (1) :224-246.

Carpenter D, Fendrick MA, Chernew M, Smith D. “Approval Times for New Drugs: Does the Source of Funding for FDA Staff Matter?” . Health Affairs – Web Exclusive. 2004;W3- 618-624.

Carpenter D. “The Political Economy of FDA Drug Approval: Processing Politics and Implications for Policy” . Health Affairs. 2004;23 (1) :52-63.

Carpenter D, Fendrick MA. “Accelerating Approval Times for New Drugs in the U.S”. The Regulatory Affairs Journal – Pharma. 2004;15 (6) :411-417.

Carpenter D. “Staff Resources Speed FDA Drug Review” . Journal of Health Policy Politics and Law. 2004;29 (3) :431-442.

Carpenter D. “Gatekeeping and the FDA’s Role in Human Subjects Protection” . Virtual Mentor [American Medical Association] . 2004;6.

Carpenter D, Lewis D. “Political Learning from Rare Events: Poisson Inference Fiscal Constraints and the Lifetime of Bureaus”. Political Analysis. 2004;12 (3) :201-232.

Carpenter D. “Protection without Capture: Dynamic Product Approval by a Politically Responsive Learning Regulator”. American Political Science Review . 2004;98 (4) :613-631. protwoc-apsr-pub.pdf

Carpenter D. Lesson, Portraiture, Method, Myth: Richard Bensel’s The Political Economy of American Industrialization, 1877-1900. 2003.

Carpenter D, Cram P, Inadomi J, Vijay S, Fendrick MA. “The Impact of a Celebrity Promotional Campaign on the Use of Colon Cancer Screening: The Case of Katie Couric” . Archives of Internal Medicine . 2003;63 :1601-1605.